Abstract
Management of patients with small renal masses (SRMs) continues to be a central focus within urological oncology. While most of these patients can be managed with surveillance, there is still a significant amount that, due to either their tumor biology or growth rate, merits active treatment. Ablation is now a guideline approved alternative to surgery in these cases. 1 This alternative is an attractive option for patients not clinically suited for surgery, with anatomical variations, prior surgeries, or endophytic tumor locations.
The study by Lucignani et al., explores the comparative efficacy of cryoablation (CA) and microwave ablation (MWA) for SRMs, using a multifaceted “trifecta” approach to assess outcomes. Defined by the absence of major complications, preservation of kidney function, and lack of local recurrence, the trifecta provides an integrative metric that reflects both clinical success and patient quality of life. This study’s findings reinforce the value of the trifecta metric and provide new insights that could refine therapeutic strategies for managing SRMs.
The authors conducted a retrospective analysis of 175 patients who underwent either CA or MWA. Of particular note is the study’s focus on the trifecta achievement rate in each cohort, yielding comparable outcomes with 59.5% for CA and 59.3% for MWA, respectively. These rates, while promising, highlight a need for further investigation into factors influencing trifecta success. The study underscores that the location of the tumor relative to the renal collecting system can significantly impact outcomes, particularly in MWA procedures, where the proximity to the collecting system was associated with reduced recurrence-free survival.
This finding on tumor location suggests that while both CA and MWA are viable options for SRM treatment; MWA outcomes may be more susceptible to the heat sink effect caused by the renal collecting system, which absorbs and dissipates thermal energy. This phenomenon potentially leads to incomplete ablation of tissue adjacent to the collecting system. The study’s multivariate logistic regression analysis supports this by indicating a lower likelihood of trifecta achievement for MWA in tumors on this particular anatomical consideration.
The authors of this study raise a relevant issue that may influence energy modality choice on clinicians practicing renal mass ablation. For patients with tumors close to the collecting system, CA may offer a more reliable outcome in achieving the trifecta. It would also be interesting for future research studies to assess whether the same heat sink principle would work the other way around for CA on tumors close to large vessels, as there is concern the circulating “warm” blood may prevent the ice ball to reaching their proximity.
Limitations of the study include its retrospective design and the lack of standardized perioperative protocols across the two institutions involved. While the sample size and scope are substantial, prospective studies that implement uniform protocols could confirm and strengthen these findings.
Lucignani et al.’s study is a valuable contribution to the ongoing evolution of SRM management, underscoring the necessity of patient-centered decision-making informed by anatomy and treatment-specific outcomes. As the trifecta measure becomes more widely adopted in the renal mass ablation realm, this study provides evidence that may guide further innovation in ablation technology and clinical strategy.